Antiandrogen Monotherapy Market Growth Driven By Increasing Prevalence of Prostate Cancer in Adult Men
Antiandrogen monotherapy is one of the newest forms of prostate cancer treatment. Increasing prevalence of prostate cancer is expected to propel growth of antiandrogen monotherapy market. According to the American Cancer Society, in 2019, there will be around 174,650 men with newly diagnosed prostate cancer in the U.S., registering a 6% increase from 2018. Antiandrogen monotherapy has revolutionized the treatment of prostate cancer as it eliminates the cause of male pattern baldness by restricting and blocking the effect of androgens on the prostate gland. It is also known as hormonal therapy, and its underlying mechanisms are similar to those of surgical removal of the testes, albeit in a very limited scope of function. By blocking the production androgen receptors, the production of DHT, the major androgen in the bloodstream, is significantly reduced. This leads to a gradual but significant reduction in the size of the prostate and its functions such as sperm production, sperm moveme...